$CPHI
China Pharma Holdings Inc Stock $cphi

$cphi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024710 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.960M	$2.921M	$8.104M
YoY Change	22.21%	1.09%	-15.95%
Cost Of Revenue	$1.782M	$2.878M	$8.598M
YoY Change	0.5%	11.24%	-7.48%
Gross Profit	$177.9K	$42.68K	-$493.9K
YoY Change	-204.99%	-85.86%	-241.41%
Gross Profit Margin	9.08%	1.46%	-6.09%
Selling, General & Admin	$562.4K	$1.175M	$2.963M
YoY Change	-17.11%	32.48%	3.87%
% of Gross Profit	316.11%	2753.16%
Research & Development	$23.01K	$28.00K	$185.9K
YoY Change	-57.43%	-48.2%	-41.73%
% of Gross Profit	12.93%	65.6%
Depreciation & Amortization	$679.9K	$639.4K	$2.701M
YoY Change	-4.72%	-10.03%	-12.54%
% of Gross Profit	382.12%	1498.17%
Operating Expenses	$575.4K	$1.212M	$3.055M
YoY Change	-22.48%	27.46%	-4.82%
Operating Profit	-$397.5K	-$1.169M	-$3.549M
YoY Change	-56.4%	80.21%	24.07%
Interest Expense	$79.45K	-$95.18K	$434.6K
YoY Change	-167.46%	-71.33%	-180.64%
% of Operating Profit
Other Income/Expense, Net	-$78.50K		-$423.9K
YoY Change	-33.35%		-21.36%
Pretax Income	-$476.0K	-$1.264M	-$3.973M
YoY Change	-53.77%	28.9%	16.87%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$476.0K	-$1.264M	-$3.973M
YoY Change	-53.77%	28.9%	16.87%
Net Earnings / Revenue	-24.28%	-43.28%	-49.02%
Basic Earnings Per Share	-$0.06		-$0.76
Diluted Earnings Per Share	-$0.06	-$0.20	-$0.76
COMMON SHARES
Basic Shares Outstanding	8.458M shares	51.64M shares	5.257M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.167M	$2.030M	$2.030M
YoY Change	-68.59%	-58.22%	-58.22%
Cash & Equivalents	$1.167M	$2.030M	$2.030M
Short-Term Investments
Other Short-Term Assets	$102.8K	$77.70K	$77.70K
YoY Change	43.15%	32.17%	32.17%
Inventory	$3.760M	$2.948M	$2.948M
Prepaid Expenses	$102.8K	$77.70K
Receivables	$549.1K	$421.5K	$421.5K
Other Receivables	$501.6K	$487.6K	$487.6K
Total Short-Term Assets	$6.081M	$5.965M	$5.965M
YoY Change	-25.53%	-34.41%	-34.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.430M	$9.973M	$10.01M
YoY Change	-25.98%	-24.9%	-25.33%
Goodwill
YoY Change
Intangibles	$1.826M	$1.807M
YoY Change		1122.59%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.28M	$11.82M	$11.82M
YoY Change	-12.44%	-12.81%	-12.81%
TOTAL ASSETS
Total Short-Term Assets	$6.081M	$5.965M	$5.965M
Total Long-Term Assets	$11.28M	$11.82M	$11.82M
Total Assets	$17.36M	$17.78M	$17.78M
YoY Change	-17.52%	-21.48%	-21.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$848.9K	$667.1K	$667.1K
YoY Change	-8.46%	-28.02%	-28.02%
Accrued Expenses	$113.8K	$404.8K	$445.3K
YoY Change	-49.42%	35.64%	16.03%
Deferred Revenue	$136.7K	$520.3K
YoY Change		147.73%
Short-Term Debt	$6.133M	$6.241M	$6.241M
YoY Change	42.62%	44.17%	44.17%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.92M	$12.74M	$12.74M
YoY Change	20.39%	21.17%	21.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.92M	$12.74M	$12.74M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.69M	$13.49M	$13.49M
YoY Change	-19.21%	-18.87%	-18.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.69M	-$36.21M
YoY Change		12.32%
Common Stock	$84.50K	$74.91K
YoY Change		58.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.669M	$4.290M	$4.290M
YoY Change
Total Liabilities & Shareholders Equity	$17.36M	$17.78M	$17.78M
YoY Change	-17.52%	-21.48%	-21.48%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$476.0K	-$1.264M	-$3.973M
YoY Change	-53.77%	28.9%	16.87%
Depreciation, Depletion And Amortization	$679.9K	$639.4K	$2.701M
YoY Change	-4.72%	-10.03%	-12.54%
Cash From Operating Activities	-$1.468M	$584.6K	-$409.5K
YoY Change	66.95%	-395.08%	63.92%
INVESTING ACTIVITIES
Capital Expenditures		-$27.27K	$402.0K
YoY Change		286.26%	-191.76%
Acquisitions
YoY Change
Other Investing Activities	$55.96K
YoY Change
Cash From Investing Activities	$55.96K	$27.27K	-$402.0K
YoY Change	-4126.19%	-486.26%	-8.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$518.2K	-672.1K	-$1.770M
YoY Change	-287.92%	-114.55%	-138.5%
NET CHANGE
Cash From Operating Activities	-$1.468M	584.6K	-$409.5K
Cash From Investing Activities	$55.96K	27.27K	-$402.0K
Cash From Financing Activities	$518.2K	-672.1K	-$1.770M
Net Change In Cash	-$863.0K	-60.21K	-$2.829M
YoY Change	-25.38%	-101.36%	-172.36%
FREE CASH FLOW
Cash From Operating Activities	-$1.468M	$584.6K	-$409.5K
Capital Expenditures		-$27.27K	$402.0K
Free Cash Flow		$611.9K	-$811.5K
YoY Change		-420.26%	-531.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34471
CY2022	dei	Entity Registrant Name EntityRegistrantName	China Pharma Holdings, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	73-1564807
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	Second Floor, No. 17, Jinpan Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Haikou
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Hainan Province
CY2022	dei	Entity Address Country EntityAddressCountry	CN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	570216
CY2022	dei	City Area Code CityAreaCode	86
CY2022	dei	Local Phone Number LocalPhoneNumber	898-6681-1730
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	CPHI
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	10601665	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8458094	shares
CY2022	dei	Auditor Name AuditorName	B F Borgers CPA PC
CY2022	dei	Auditor Location AuditorLocation	Lakewood, Colorado
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2029971	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4859059	usd
CY2022Q4	cphi	Bankers Acceptances BankersAcceptances	13784	usd
CY2021Q4	cphi	Bankers Acceptances BankersAcceptances	91362	usd
CY2022Q4	cphi	Trade Accounts Receivable Less Allowance TradeAccountsReceivableLessAllowance	16739527	usd
CY2021Q4	cphi	Trade Accounts Receivable Less Allowance TradeAccountsReceivableLessAllowance	18312707	usd
CY2022Q4	cphi	Trade Accounts Receivable Less Allowance For Doubtful Accounts TradeAccountsReceivableLessAllowanceForDoubtfulAccounts	421531	usd
CY2021Q4	cphi	Trade Accounts Receivable Less Allowance For Doubtful Accounts TradeAccountsReceivableLessAllowanceForDoubtfulAccounts	714475	usd
CY2022Q4	cphi	Other Receivables Less Allowance For Doubtful Accounts OtherReceivablesLessAllowanceForDoubtfulAccounts	27149	usd
CY2021Q4	cphi	Other Receivables Less Allowance For Doubtful Accounts OtherReceivablesLessAllowanceForDoubtfulAccounts	32210	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	29139	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	29564	usd
CY2022Q4	cphi	Advance To Supplies AdvanceToSupplies	444637	usd
CY2021Q4	cphi	Advance To Supplies AdvanceToSupplies	471	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2947787	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3339686	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	77697	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	58792	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5964546	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9093409	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9973065	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13280559	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39046	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127958	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1807486	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	147841	usd
CY2022Q4	us-gaap	Assets Assets	17784143	usd
CY2021Q4	us-gaap	Assets Assets	22649767	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	667082	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	926749	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	404807	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	298452	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	2390063	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1884161	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	520295	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	210028	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2475840	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2779690	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40445	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	85282	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2440915	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4328936	usd
CY2022Q4	us-gaap	Long Term Construction Loan Current LongTermConstructionLoanCurrent	3800000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12739447	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10513298	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5250000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44181	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	754698	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	824407	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13494145	usd
CY2021Q4	us-gaap	Liabilities Liabilities	16631886	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7490896	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7490896	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4733956	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4733956	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74909	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47340	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28853520	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25645367	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36211496	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32238655	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11573065	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12563829	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4289998	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6017881	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17784143	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22649767	usd
CY2022	us-gaap	Revenues Revenues	8104092	usd
CY2021	us-gaap	Revenues Revenues	9641925	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	8598008	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	9292655	usd
CY2022	us-gaap	Gross Profit GrossProfit	-493916	usd
CY2021	us-gaap	Gross Profit GrossProfit	349270	usd
CY2022	us-gaap	Selling Expense SellingExpense	1069785	usd
CY2021	us-gaap	Selling Expense SellingExpense	1495007	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1893269	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1651024	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	185858	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	318964	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-93851	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-255215	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3055061	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3209780	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3548977	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2860510	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	10755	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	3035	usd
CY2022	us-gaap	Interest Expense InterestExpense	434619	usd
CY2021	us-gaap	Interest Expense InterestExpense	542001	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-423864	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-538966	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3972841	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3399476	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3972841	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3399476	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-990764	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	218383	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4963605	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3181093	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5256855	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4612926	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8004531	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15243	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1179200	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-3399476	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	218383	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6017881	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1707452	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	36270	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1450000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3972841	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-990764	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4289998	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3972841	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3399476	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2700533	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3087820	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-93851	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-255215	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	78270	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	15243	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-250000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	170194	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	545534	usd
CY2022	cphi	Advances To Suppliers AdvancesToSuppliers	459959	usd
CY2021	cphi	Advances To Suppliers AdvancesToSuppliers	-1798	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-689104	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1011905	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-187734	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-332779	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	692190	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	415309	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	339659	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-520414	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	24722	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21505	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-409545	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-249838	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	401964	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	438055	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-401964	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-438055	usd
CY2021	us-gaap	Repayments Of Construction Loans Payable RepaymentsOfConstructionLoansPayable	2325039	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	-2140921	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	-2526542	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	564965	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	28962	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1183414	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	223013	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	562659	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	5000000	usd
CY2021	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	3828564	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1770007	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4597738	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-247572	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8439	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2829088	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3901406	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4859059	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	957653	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2029971	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4859059	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	141797	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	218232	usd
CY2022	cphi	Accounts Receivable Collected With Bankers Acceptances AccountsReceivableCollectedWithBankersAcceptances	503383	usd
CY2021	cphi	Accounts Receivable Collected With Bankers Acceptances AccountsReceivableCollectedWithBankersAcceptances	601021	usd
CY2022	cphi	Inventory Purchased With Bankers Acceptance Note InventoryPurchasedWithBankersAcceptanceNote	575713	usd
CY2021	cphi	Inventory Purchased With Bankers Acceptance Note InventoryPurchasedWithBankersAcceptanceNote	565079	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	168606	usd
CY2022	cphi	Conversion Of Officer Wages To Common Stock ConversionOfOfficerWagesToCommonStock	1707452	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	1179200	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2000000	usd
CY2022Q4	cphi	Accumulated Deficit AccumulatedDeficit	36200000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse Stock Split </i></b>– Effective March 6, 2023, the Company implemented a 1-for -10 reverse stock split as more fully discussed in Note 14. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1552229	shares
CY2022Q4	us-gaap	Dividends Stock DividendsStock	1707452	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.1
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y8M12D
CY2022	us-gaap-sup	Management And Service Fees Rate ManagementAndServiceFeesRate	0.15	pure
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4747142	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting Estimates </i>- </b>The methodology used to prepare the Company’s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance, valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used to calculate derivative liabilities. Therefore, actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	93851	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	255215	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	520295	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	210028	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5147051	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1807486	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	147841	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit Risk</i></b> – The carrying amount of accounts receivable included in the balance sheet represents the Company’s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer’s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate have not exceeded management’s estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	cphi	Purchase Of Common Stock Shares PurchaseOfCommonStockShares	96500	shares
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	126667	shares
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1839641	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2131584	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	557146	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	622380	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	551000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	585722	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2947787	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3339686	usd
CY2022Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	404427	usd
CY2021Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	441783	usd
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	9391433	usd
CY2021Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	10258885	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	27780585	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	30122235	usd
CY2022Q4	cphi	Motor Vehicle Gross MotorVehicleGross	438138	usd
CY2021Q4	cphi	Motor Vehicle Gross MotorVehicleGross	337375	usd
CY2022Q4	cphi	Office Equipment Gross OfficeEquipmentGross	308847	usd
CY2021Q4	cphi	Office Equipment Gross OfficeEquipmentGross	278892	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38323430	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41439170	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28350365	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28158611	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	9973065	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	13280559	usd
CY2022	us-gaap	Depreciation Depreciation	2663975	usd
CY2021	us-gaap	Depreciation Depreciation	3049706	usd
CY2022	cphi	Intangible Assets Useful Life Description IntangibleAssetsUsefulLifeDescription	Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36558	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38114	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6554628	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5294892	usd
CY2022Q4	us-gaap	Due From Related Parties DueFromRelatedParties	1121273	usd
CY2021Q4	us-gaap	Due From Related Parties DueFromRelatedParties	1425123	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	951506	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	211939	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	211939	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	206055	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	176632	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	176632	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	824289	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1807486	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	951506	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	715506	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	372578	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	327033	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1065979	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	841622	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	2390063	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	1884161	usd
CY2022Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	1354567	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.01	pure
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13546	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	13546	usd
CY2022Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	372578	usd
CY2021Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	327033	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	715506	usd
CY2021Q3	us-gaap	Notes Payable NotesPayable	1179200	usd
CY2021Q3	cphi	Compensation Converted CompensationConverted	176000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0405	pure
CY2021Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0417	pure
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0417	pure
CY2022Q4	us-gaap	Construction Loan ConstructionLoan	7300000	cny
CY2022Q4	us-gaap	Construction Loan ConstructionLoan	1000000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.039	pure
CY2022Q4	us-gaap	Construction Loan ConstructionLoan	3800000	cny
CY2022Q4	us-gaap	Construction Loan ConstructionLoan	560000	usd
CY2022Q4	us-gaap	Construction Loan ConstructionLoan	440000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	53283	usd
CY2020Q3	us-gaap	Construction Loan ConstructionLoan	3200000	cny
CY2020Q4	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	2343340	cny
CY2020Q4	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	300000	usd
CY2022Q4	cphi	Interest Rate InterestRate	0.045	pure
CY2021Q3	us-gaap	Construction Loan ConstructionLoan	3200000	cny
CY2021Q3	us-gaap	Construction Loan ConstructionLoan	800000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	21528	usd
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	22258	usd
CY2022Q4	cphi	Interest Amount InterestAmount	0	usd
CY2021Q4	cphi	Interest Amount InterestAmount	16051	usd
CY2021Q3	us-gaap	Construction Loan ConstructionLoan	10000000	cny
CY2021Q3	us-gaap	Construction Loan ConstructionLoan	1540000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0385	pure
CY2013Q2	us-gaap	Construction Loan ConstructionLoan	80000000	cny
CY2013Q2	us-gaap	Construction Loan ConstructionLoan	13000000	usd
CY2021Q4	cphi	Interest Rate InterestRate	0.0539	pure
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2325039	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15000000	cny
CY2021Q4	us-gaap	Debt Instrument Term DebtInstrumentTerm	P15M
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5250000	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	5000000	usd
CY2021Q4	cphi	Original Issue Discount OriginalIssueDiscount	250000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	350000	pure
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	15
CY2022	cphi	Convertible Note ConvertibleNote	175000	shares
CY2022	cphi	Convertible Note Conversion Price ConvertibleNoteConversionPrice	30
CY2022	cphi	Interest Accrues On Note Description InterestAccruesOnNoteDescription	Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
CY2022	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	500000	usd
CY2022	cphi	Percentage Of Common Stock Price On Weighted Average Price PercentageOfCommonStockPriceOnWeightedAveragePrice	0.85	pure
CY2021Q4	cphi	Note Redeemable Into Shares NoteRedeemableIntoShares	881143	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.95817
CY2022	cphi	Note Redeemable Into Shares NoteRedeemableIntoShares	3836070	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	85
CY2022	cphi	Weighted Average Price WeightedAveragePrice	0.991
CY2021	cphi	Original Issue Discount OriginalIssueDiscount	250000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	250314	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	279979	usd
CY2022Q1	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	100000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.113
CY2022Q1	us-gaap	Shares Issued SharesIssued	32123	shares
CY2022Q1	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	200000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.129
CY2022Q1	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q1	cphi	Common Stock Issued To Investor CommonStockIssuedToInvestor	63918	shares
CY2022Q2	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	200000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.98
CY2022Q2	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q2	us-gaap	Shares Issued SharesIssued	101010	shares
CY2022Q3	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	200000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.755
CY2022Q3	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q3	us-gaap	Shares Issued SharesIssued	113960	shares
CY2022Q4	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.12
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q4	cphi	Common Stock Issued To Investor1 CommonStockIssuedToInvestor1	89286	shares
CY2022Q4	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.829
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	120627	shares
CY2022Q4	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	310000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.829
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	373945	shares
CY2022Q4	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	90000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.91
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	98901	shares
CY2022Q4	cphi	Redeem Of Outstanding Note RedeemOfOutstandingNote	150000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.829
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.85	pure
CY2022Q4	us-gaap	Shares Issued SharesIssued	180905	shares
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	78092	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	92085	usd
CY2022	cphi	Cash Flow For Operating Lease CashFlowForOperatingLease	82015	usd
CY2021	cphi	Cash Flow For Operating Lease CashFlowForOperatingLease	98845	usd
CY2022Q4	cphi	Operating Lease Rights Of Use Assets OperatingLeaseRightsOfUseAssets	39046	usd
CY2021Q4	cphi	Operating Lease Rights Of Use Assets OperatingLeaseRightsOfUseAssets	127958	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	40445	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	85282	usd
CY2022	cphi	Weighted Averages Remaining Lease Term WeightedAveragesRemainingLeaseTerm	P0Y6M
CY2022	cphi	Weighted Average Discount Rate WeightedAverageDiscountRate	0.0475	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	41007	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	41007	usd
CY2022Q4	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	562	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	40445	usd
CY2022	cphi	Less Operating Lease Liabilities Current Portion LessOperatingLeaseLiabilitiesCurrentPortion	40445	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-973717	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-849869	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8416	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8440	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	965301	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	841429	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	4184882	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	4578177	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses	6787	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses	8052	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	34921	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	137549	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3201	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3201	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1087328	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1187760	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	9782172	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	10685714	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	349	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	376	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5036114	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5779437	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1849800	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1602243	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21985554	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23982509	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21985554	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23982509	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	754698	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	824407	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20100000	usd
CY2022	cphi	Net Operating Loss Carry Forwards Expiration Description NetOperatingLossCarryForwardsExpirationDescription	Approximately $6.0 million of these carryforwards expired in December 2022. The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
CY2022Q4	cphi	Valuation Allowance For Deferred Tax Assets ValuationAllowanceForDeferredTaxAssets	21985554	usd
CY2021Q4	cphi	Valuation Allowance For Deferred Tax Assets ValuationAllowanceForDeferredTaxAssets	23982509	usd
CY2022Q4	us-gaap	Customers Liability For Acceptances Net CustomersLiabilityForAcceptancesNet	13784	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	13784	usd
CY2021Q4	us-gaap	Customers Liability For Acceptances Net CustomersLiabilityForAcceptancesNet	91362	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	91362	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022	cphi	Aftertax Net Income Percentage AftertaxNetIncomePercentage	0.10	pure
CY2022	cphi	Reserve Account Balances Percentage ReserveAccountBalancesPercentage	0.50	pure
CY2022	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	8145000	usd
CY2021	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	8145000	usd
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	500000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	500000	shares
CY2022	cphi	Total Option Outstanding TotalOptionOutstanding	66500	shares
CY2022Q4	cphi	Additional Shares Available For Issuance AdditionalSharesAvailableForIssuance	910000	shares
CY2022Q4	cphi	Common Stock Pursuant CommonStockPursuant	30000	shares
CY2022Q4	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	42000	usd
CY2022Q4	cphi	Closing Market Price ClosingMarketPrice	1.4
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	90000	usd
CY2022Q4	cphi	Purchaseof Common Stock Shares PurchaseofCommonStockShares	60000	shares
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5.6
CY2022Q4	cphi	Fair Value Of Options Granted FairValueOfOptionsGranted	36270	usd
CY2022Q4	cphi	Closing Market Price ClosingMarketPrice	1.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.155	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0384	pure
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y6M
CY2021Q3	cphi	Purchaseof Common Stock Shares PurchaseofCommonStockShares	6500	shares
CY2021Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	14.7
CY2021Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	15243	usd
CY2021Q3	cphi	Market Price Per Share MarketPricePerShare	6.7
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.184	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0075	pure
CY2021Q3	cphi	Expected Lifes ExpectedLifes	P1Y6M
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	cphi	Conversion Of Officer Wages To Common Stock ConversionOfOfficerWagesToCommonStock		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q4	cphi	Operating Lease Liabilities Net Of Current Portion OperatingLeaseLiabilitiesNetOfCurrentPortion		usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes		usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001106644

Files In Submission

Name	View Source	Status
0001213900-23-024710-index-headers.html	Edgar Link	pending
0001213900-23-024710-index.html	Edgar Link	pending
0001213900-23-024710.txt	Edgar Link	pending
0001213900-23-024710-xbrl.zip	Edgar Link	pending
cphi-20221231.xsd	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_005.jpg	Edgar Link	pending
ex3-1_006.jpg	Edgar Link	pending
f10k2022ex10-11_china.htm	Edgar Link	pending
f10k2022ex23-1_china.htm	Edgar Link	pending
f10k2022ex3-1_china.htm	Edgar Link	pending
f10k2022ex31-1_china.htm	Edgar Link	pending
f10k2022ex31-2_china.htm	Edgar Link	pending
f10k2022ex32-1_china.htm	Edgar Link	pending
f10k2022_chinapharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
cphi-20221231_cal.xml	Edgar Link	unprocessable
cphi-20221231_def.xml	Edgar Link	unprocessable
cphi-20221231_lab.xml	Edgar Link	unprocessable
cphi-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_chinapharma_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPHI
China Pharma Holdings Inc Stock $cphi

2023 Q1 Form 10-K Financial Statement

#000121390023024710 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPHI China Pharma Holdings Inc Stock $cphi

2023 Q1 Form 10-K Financial Statement

#000121390023024710 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPHI
China Pharma Holdings Inc Stock $cphi